7 handpicked stocks

Top Dividend Paying Stocks

These reliable companies have a proven track record of sharing profits with investors through regular dividend payments. Carefully selected by our professional analysts, these stocks offer the potential for both steady income and long-term growth.

stock
stock
stock
stock
stock
stock
stock
Author avatar

Han Tan | Market Analyst

Updated 2 days ago | Published at mai 3

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

JNJ

Johnson & Johnson

JNJ

Current price

$177.57

KO

Coca-Cola Company, The

KO

Current price

$69.58

ABBV

AbbVie Inc.

ABBV

Current price

$206.80

About This Group of Stocks

1

Our Expert Thinking

These stocks represent companies that consistently return a portion of their profits to shareholders through dividend payments. Many have increased their dividends for at least 10 consecutive years, demonstrating financial stability and a commitment to rewarding investors over time.

2

What You Need to Know

Dividend-paying stocks can provide regular income alongside potential stock price growth. Each company's management decides quarterly how much cash to distribute as dividends. These selections offer a balance between ongoing income and the possibility of long-term appreciation.

3

Why These Stocks

We've handpicked companies with impressive track records of not just paying dividends but increasing them year after year. These stocks represent established businesses with strong cash flows and management teams committed to sharing success with shareholders.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+0.91%

Group Performance Snapshot

0.91%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 0.91% over the next year.

5 of 7

Stocks Rated Buy by Analysts

5 of 7 assets in this group are rated Buy by professional analysts.

1%

Group Growth

This group averaged a 1% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💰

Get Paid While You Wait

Unlike growth-only stocks, these companies pay you regular dividends while you hold them. It's like earning interest on your investment even before you sell.

👑

Royal Treatment for Investors

These companies have increased their dividend payments for 10+ consecutive years, showing their commitment to treating shareholders like royalty through good times and bad.

🔄

Double Growth Potential

Enjoy the best of both worlds: regular income from dividends plus the potential for your investment to grow in value over time. It's two ways to build wealth with one investment.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.